CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Event**: FY Conference held on December 04, 2025 - **Key Technology**: Probody technology, which masks therapeutic proteins to enhance targeting in tumor tissues while reducing effects on healthy tissues [1][3][4] Core Points and Arguments Probody Technology - Probody technology allows for selective binding of therapeutic proteins in tumor tissues by masking them, which is cleaved by tumor-associated proteases [3][4] - This innovative approach has been validated through encouraging phase one data on CX-2051 for colorectal cancer [1][2] CX-2051 Development - CX-2051 targets EpCAM, a tumor antigen abundant in colorectal cancer, but previously faced challenges due to toxicity in normal tissues [6][7] - The phase one study showed a confirmed response rate of 28% in a late-stage metastatic colorectal cancer patient population, with a median of four prior therapies [10][11] - The drug demonstrated a progression-free survival of 5.8 months and a 94% disease control rate, indicating significant efficacy in a difficult-to-treat population [11] Future Development Plans for CX-2051 - The company plans to expand the study to include about 100 patients and aims to provide updates on efficacy and safety in Q1 of the following year [12][13] - The immediate goal is to get CX-2051 on a path to registration as a monotherapy, with potential studies against standard care in later lines of therapy [15][17] - There is a vision for CX-2051 to potentially replace irinotecan in earlier lines of colorectal cancer therapy [16][17] CX-801 Development - CX-801, a masked interferon alpha-2b, is being developed for melanoma, leveraging the same masking strategy to improve tolerability while activating the immune response [21][22] - Early data showed activation of interferon-responsive genes and recruitment of T cells in the tumor microenvironment, setting the stage for combination therapy with Keytruda [24][25] Other Programs and Partnerships - CytomX is also exploring CX-908, a dual masked T cell engager targeting P-cadherin and CD3, with promising preclinical results [26][27] - The company is open to partnerships for further development, especially in the T cell engager space, while maintaining a focus on productization [28][29] Financial Position - As of the end of Q3 2025, CytomX had $144 million in cash, which has since increased to approximately $158 million, providing funding into Q2 2027 [33] - This financial position supports ongoing clinical studies and the expansion of their therapeutic pipeline [33] Additional Insights - The company has experienced a transformational year in 2025, with significant advancements in their clinical programs and technology validation [5][33] - There is a strong emphasis on maintaining urgency and speed in development, with potential for broadening the application of their Probody platform across various solid tumors [18][30]